These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2974555)

  • 1. [Naloxone and naltrexone in the treatment of chronic obstructive bronchopneumopathies].
    Caillaud D; Bedu M; Coudert J; Molina C
    Presse Med; 1988 Oct; 17(38):2036. PubMed ID: 2974555
    [No Abstract]   [Full Text] [Related]  

  • 2. [Naloxone and naltrexone in the therapy of advanced COPD].
    Foresti V; De Filippi G; Casati O; Zubani R; Scolari N
    Recenti Prog Med; 1991 Apr; 82(4):230-2. PubMed ID: 1857843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone and naltrexone. Application in COPD.
    Reents SB; Beck CA
    Chest; 1988 Jan; 93(1):217-9. PubMed ID: 3121260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of naloxone on the respiratory responses to hypoxia in chronic obstructive pulmonary disease.
    Santiago TV; Sheft SA; Khan AU; Edelman NH
    Am Rev Respir Dis; 1984 Aug; 130(2):183-6. PubMed ID: 6465672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of naloxone on breathing pattern in patients with chronic obstructive pulmonary disease with and without hypercapnia.
    Tobin MJ; Jenouri G; Sackner MA
    Respiration; 1983; 44(6):419-24. PubMed ID: 6648050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of naloxone on arterial gases in chronically obstructed patients with acute respiratory failure.
    Montserrat JM; Ballester E; Sopeña JJ; Picado C
    Eur J Respir Dis; 1985 Jan; 66(1):77-9. PubMed ID: 3979482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of heparin in the treatment of decompensated chronic obstructive bronchopneumopathies].
    Wipf R; Stinghe R
    Rev Med Suisse Romande; 1977 Nov; 97(11):525-30. PubMed ID: 601376
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiretroviral activity of naloxone and naltrexone.
    Mahayni H; Minor JR
    Am J Hosp Pharm; 1991 Nov; 48(11):2480-1. PubMed ID: 1746587
    [No Abstract]   [Full Text] [Related]  

  • 9. Opiate antagonists for the treatment of schizophrenia.
    Welch EB; Thompson DF
    J Clin Pharm Ther; 1994 Oct; 19(5):279-83. PubMed ID: 7806598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of narcotic antagonists on self-injurious behavior: a single case study.
    Bernstein GA; Hughes JR; Mitchell JE; Thompson T
    J Am Acad Child Adolesc Psychiatry; 1987 Nov; 26(6):886-9. PubMed ID: 3429408
    [No Abstract]   [Full Text] [Related]  

  • 11. [Our experience with a prolonged-action corticoid, in intramuscular administration, in the treatment of chronic obstructive bronchopneumopathies].
    Gallina G; Rampazzo F
    Clin Ter; 1978 Aug; 86(3):241-8. PubMed ID: 743861
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of obstructive bronchopneumopathies with 21-dexamethasone isonicotinate in aerosol].
    Beran G
    Schweiz Rundsch Med Prax; 1971 Sep; 60(37):1233-6. PubMed ID: 5094909
    [No Abstract]   [Full Text] [Related]  

  • 14. Naltrexone in the treatment of opiate dependence.
    Resnick RB; Washton AM; Thomas MA; Kestenbaum RS
    NIDA Res Monogr; 1978; (19):321-32. PubMed ID: 218108
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-inflammatory therapeutic activity of fenspiride in the treatment of chronic bronchopneumopathies].
    Cardaci G; Mancini G; Vittore F; Quarantotto E; Pieri S; Benassi F
    Clin Ter; 1982 May; 101(3):275-95. PubMed ID: 6124335
    [No Abstract]   [Full Text] [Related]  

  • 16. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.
    Loimer N; Lenz K; Schmid R; Presslich O
    Am J Psychiatry; 1991 Jul; 148(7):933-5. PubMed ID: 2053636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of using cardioselective beta blocking agents in patients with chronic obstructive bronchopneumopathies].
    Giorgis GE; Galietti F; Miravalle C; Barberis S; Massaglia GM; Onoscuri E
    Minerva Med; 1986 Jun; 77(26):1255-8. PubMed ID: 2873530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the therapeutic activity of aminosidine, in inhalational administration, in chronic obstructive bronchopneumopathies].
    Del Bufalo C; Pajello M; Cavalli A; Fabbri M; Gunella G
    G Clin Med; 1979 Dec; 60(12):991-1009. PubMed ID: 540676
    [No Abstract]   [Full Text] [Related]  

  • 19. Protective effect of nalmefene and naloxone on the ischemically damaged small bowel.
    Lopez J; Naujokat P; Xavier R; Walters W; Toledo-Pereyra LH
    Transplant Proc; 1991 Oct; 23(5):2448-9. PubMed ID: 1926426
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
    Kosten TR; Morgan C; Kleber HD
    NIDA Res Monogr; 1992; 121():101-19. PubMed ID: 1406906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.